Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOTH Hoth Therapeutics	$1.43 -0.7%	$1.10	$0.58 ▼ $3.80	$18.89M	0.67	3.71 million shs	246,793 shs
JAGX Jaguar Animal Health	$2.39 -11.5%	$4.48	$2.28 ▼ $110.75	$2.44M	0.56	56,460 shs	326,196 shs
MLND Millendo Therapeutics	$6.90 -0.7%	$4.00	$0.92 ▼ $16.95	$131.40M	0.48	1.52 million shs	42,293 shs
NEOS Neos Therapeutics	$1.15	$1.06	$0.45 ▼ $1.68	$57.22M	1.5	7.44 million shs	15.01 million shs
TNXP Tonix Pharmaceuticals	$42.78 +4.7%	$32.58	$6.76 ▼ $130.00	$314.73M	2.05	970,000 shs	1.03 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOTH Hoth Therapeutics	-0.69%	+21.19%	+10.00%	+77.33%	+60.67%
JAGX Jaguar Animal Health	-11.48%	-5.91%	-31.52%	-53.23%	-97.65%
MLND Millendo Therapeutics	0.00%	-2.52%	+5.14%	-0.14%	+211.66%
NEOS Neos Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TNXP Tonix Pharmaceuticals	+4.67%	+20.71%	+33.77%	+151.65%	-28.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HOTH Hoth Therapeutics	3.1491 of 5 stars	3.6	5.0	0.0	0.0	3.3	0.0	0.6
JAGX Jaguar Animal Health	2.7217 of 5 stars	3.5	5.0	0.0	0.0	2.2	0.0	0.6
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NEOS Neos Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	2.6636 of 5 stars	3.5	2.0	0.0	0.0	1.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HOTH Hoth Therapeutics	3.25	Buy	$4.00	179.72% Upside
JAGX Jaguar Animal Health	3.00	Buy	$60.00	2,410.46% Upside
MLND Millendo Therapeutics	0.00	N/A	N/A	N/A
NEOS Neos Therapeutics	0.00	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	3.00	Buy	$585.00	1,267.46% Upside

Current Analyst Ratings Breakdown

Latest JAGX, MLND, HOTH, TNXP, and NEOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/19/2025	JAGX Jaguar Animal Health	First Berlin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/15/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
JAGX Jaguar Animal Health	$11.69M	0.21	N/A	N/A	$12.29 per share	0.19
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
NEOS Neos Therapeutics	$64.65M	0.89	N/A	N/A	($0.12) per share	-9.58
TNXP Tonix Pharmaceuticals	$10.04M	31.34	N/A	N/A	$31.82 per share	1.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)
JAGX Jaguar Animal Health	-$38.49M	N/A	0.00	N/A	N/A	-343.92%	-432.91%	-71.25%	8/12/2025 (Estimated)
MLND Millendo Therapeutics	-$36.41M	N/A	0.00	∞	N/A	N/A	-91.03%	-72.44%	N/A
NEOS Neos Therapeutics	-$16.90M	-$0.34	N/A	N/A	N/A	-38.35%	N/A	-28.46%	N/A
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	N/A	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)

Latest JAGX, MLND, HOTH, TNXP, and NEOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	JAGX Jaguar Animal Health	-$7.13	N/A	N/A	N/A	$3.27 million	N/A
8/8/2025	N/A	HOTH Hoth Therapeutics	-$0.27	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	JAGX Jaguar Animal Health	-$18.50	-$16.70	+$1.80	-$16.70	$3.29 million	$3.50 million
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
JAGX Jaguar Animal Health	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A
NEOS Neos Therapeutics	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HOTH Hoth Therapeutics	N/A	15.09	15.08
JAGX Jaguar Animal Health	22.20	1.08	0.70
MLND Millendo Therapeutics	N/A	6.39	6.39
NEOS Neos Therapeutics	N/A	0.66	0.53
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HOTH Hoth Therapeutics	7.08%
JAGX Jaguar Animal Health	12.04%
MLND Millendo Therapeutics	N/A
NEOS Neos Therapeutics	33.13%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
HOTH Hoth Therapeutics	6.92%
JAGX Jaguar Animal Health	0.38%
MLND Millendo Therapeutics	N/A
NEOS Neos Therapeutics	3.80%
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable
JAGX Jaguar Animal Health	50	1.02 million	1.01 million	No Data
MLND Millendo Therapeutics	12	19.04 million	N/A	Not Optionable
NEOS Neos Therapeutics	213	49.76 million	N/A	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable

JAGX, MLND, HOTH, TNXP, and NEOS Headlines

Recent News About These Companies

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 5.8% - Time to Sell?

July 11, 2025 | marketbeat.com

Tonix up after peer reviewed data for pain therapy and new data for mpox vaccine

July 10, 2025 | msn.com

Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results

July 10, 2025 | msn.com

Tonix Pharmaceuticals (TNXP) Surges 10% on Phase 3 Data Release

July 10, 2025 | gurufocus.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.4% - Should You Buy?

July 10, 2025 | marketbeat.com

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...

July 10, 2025 | gurufocus.com

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...

July 10, 2025 | gurufocus.com

Tonix Pharmaceuticals (TNXP) Unveils Promising TNX-801 Vaccine Data | TNXP Stock News

July 10, 2025 | gurufocus.com

Tonix Pharma Unveils Promising TNX-801 Vaccine Findings

July 10, 2025 | tipranks.com

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

July 10, 2025 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 6.5% Higher - Here's Why

July 9, 2025 | marketbeat.com

Tonix Pharma Publishes Phase 3 Trial Results

July 9, 2025 | tipranks.com

Tonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia Management

July 9, 2025 | quiverquant.comQ

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

July 9, 2025 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Here's Why

July 7, 2025 | marketbeat.com

Tonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against Monkeypox

July 7, 2025 | quiverquant.comQ

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

July 7, 2025 | globenewswire.com

TNXP Tonix Pharmaceuticals Holding Corp. - Seeking Alpha

July 4, 2025 | seekingalpha.com

Tonix Pharmaceuticals' Combination Therapy of mTNX-1700 and Anti-PD1 Antibody Shows Promising Results in Gastric Cancer Models

July 2, 2025 | quiverquant.comQ

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

July 2, 2025 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% - Here's Why

July 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAGX, MLND, HOTH, TNXP, and NEOS Company Descriptions

Hoth Therapeutics NASDAQ:HOTH

$1.43 -0.01 (-0.69%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$1.40 -0.03 (-2.38%)

As of 07/14/2025 07:58 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Jaguar Animal Health NASDAQ:JAGX

$2.39 -0.31 (-11.48%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$2.45 +0.06 (+2.47%)

As of 07/14/2025 07:58 PM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Millendo Therapeutics NASDAQ:MLND

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

Neos Therapeutics NASDAQ:NEOS

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.

Tonix Pharmaceuticals NASDAQ:TNXP

$42.78 +1.91 (+4.67%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$44.07 +1.29 (+3.01%)

As of 04:00 AM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time